Out of hospital antithrombotic prophylaxis after total hip replacement: Low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis

被引:0
作者
Sarasin, FP
Bounameaux, H
机构
[1] Univ Geneva, Hop Cantonal, Dept Internal Med, Sch Med, CH-1211 Geneva 14, Switzerland
[2] Univ Geneva, Hop Cantonal, Med Clin 1, Sch Med, CH-1211 Geneva, Switzerland
[3] Univ Geneva, Hop Cantonal, Med Clin 2, Sch Med, CH-1211 Geneva 14, Switzerland
[4] Univ Geneva, Hop Cantonal, Sch Med, Div Angiol & Hemostasis, CH-1211 Geneva 14, Switzerland
关键词
deep vein thrombosis; hip replacement; antithrombotic prophylaxis; cost-effectiveness;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Several studies ha e suggested that after hip replacement the risk of deep vein thrombosis and subsequent pulmonary embolism (PE) may persist for some weeks. Antithrombotic prophylaxis, however, is generally stopped at hospital discharge. Using a Markov-based decision analyses. we measured the clinical and economical consequences of extending prophylaxis after hospital discharge up to 4 weeks and 6 weeks. using either low-molecular-weight heparin (LMWH), warfarin. or aspirin. In the reference strategy. antithrombotic prophylaxis was stopped at hospital discharge, Outcome measures included the number of PE prevented, major haemorrhages induced. overall costs in Euro (EUR) and specific costs generated by each PE prevented for all strategies. Extending prophylaxis up to 4 weeks after discharge was safe and cost saving for all prophylactic regimens. although LMWH was the most effective strategy. Our results were most sensitive to the rate of haemorrhages, the efficacy of treatment and its costs. Specifically. the number of PEs prevented exceeded that of haemorrhages induced if the efficacy of antithrombotic prophylaxis was greater than or equal to40% (assuming a low rate of haemorrhages of 0.1% per week), and greater than or equal to70% (assuming a high rate of haemorrhages of 0.25% per week), LMWH and warfarin remained cost saving unless their costs were more than doubled compared to that of baseline value. Although less effective than LMWH and warfarin, prophylaxis with aspirin was cost saving in all scenarios tested. Extending prophylaxis up to () weeks vas also effective (the number of PEs prevented overwhelmed that of major haemorrhages induced), but only for the scenario of a low bleeding risk (0.1%/week). In this strategy, aspirin remained cost saving. while the costs for each PE prevented became high (EUR 10,000 to EUR 20,000) if the costs of LMWH and warfarin increased. After hip replacement. extending antithrombotic prophylaxis up to 4 weeks after hospital discharge is effective and cost saving. Although LMWH is the most effective strategy, warfarin, and to a lesser extent aspirin may be alternate options if ressources are a major concern. Extending prophylaxis up to 6 weeks is more risky in patients at high bleeding risk, and generated additional costs.
引用
收藏
页码:586 / 592
页数:7
相关论文
共 36 条
  • [1] EFFICACY AND COST OF LOW-MOLECULAR-WEIGHT HEPARIN COMPARED WITH STANDARD HEPARIN FOR THE PREVENTION OF DEEP-VEIN THROMBOSIS AFTER TOTAL HIP-ARTHROPLASTY
    ANDERSON, DR
    OBRIEN, BJ
    LEVINE, MN
    ROBERTS, R
    WELLS, PS
    HIRSH, J
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (11) : 1105 - 1112
  • [2] [Anonymous], 1994, BMJ
  • [3] DIHYDROERGOTAMINE HEPARIN IN THE PREVENTION OF DEEP-VEIN THROMBOSIS AFTER TOTAL HIP-REPLACEMENT - A CONTROLLED, PROSPECTIVE, RANDOMIZED MULTICENTER TRIAL
    BEISAW, NE
    COMEROTA, AJ
    GROTH, HE
    MERLI, GJ
    WEITZ, HH
    ZIMMERMAN, RC
    DISERIO, FJ
    SASAHARA, AA
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1988, 70A (01) : 2 - 10
  • [4] Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
    Bergqvist, D
    Benoni, G
    Bjorgell, O
    Fredin, H
    Hedlundh, U
    Nicolas, S
    Nilsson, P
    Nylander, G
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) : 696 - 700
  • [5] Prevention of venous thromboembolism
    Clagett, GP
    Anderson, FA
    Geerts, W
    Heit, JA
    Knudson, M
    Lieberman, JR
    Merli, GJ
    Wheeler, HB
    [J]. CHEST, 1998, 114 (05) : 531S - 560S
  • [6] REDUCTION IN FATAL PULMONARY-EMBOLISM AND VENOUS THROMBOSIS BY PERIOPERATIVE ADMINISTRATION OF SUBCUTANEOUS HEPARIN - OVERVIEW OF RESULTS OF RANDOMIZED TRIALS IN GENERAL, ORTHOPEDIC, AND UROLOGIC SURGERY
    COLLINS, R
    SCRIMGEOUR, A
    YUSUF, S
    PETO, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (18) : 1162 - 1173
  • [7] Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26
  • [8] Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement - A randomized, double-blind, placebo-controlled trial
    Heit, JA
    Elliott, CG
    Trowbridge, AA
    Morrey, BF
    Gent, M
    Hirsh, J
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (11) : 853 - +
  • [9] HOECK JA, 1992, THROMB HAEMOSTASIS, V67, P28
  • [10] HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279